Upper GI 2017

3/28/2017

OEO2 update

OE02 update

Resection Details

– Updated results – Overall survival (from randomisation)

CS

S

Number having surgery Median time to surgery Perioperative deaths

361

386

63 days

16 days

HR (95% CI) = 0.84 (0.72, 0.98) p=0.03

CS

36 (10%)

40 (10%)

S

R0

60%

55%

R1

18%

15%

# at risk

R2

9%

13%

S CS

Inoperable

5%

14%

ASGBI 2008

ASGBI 2008

Surgery

Treatment and Surgery

CF (N=451) ECX (N=446) n % n % P- value 411 91% 387 87% 0.043

897patients

Surgery performed

Yes

CF (451)

ECX(446)

No

40 37

59 44

9%

13%

Reason for no surgery

PD, inoperable, co- morbidity

1cycle (14,3%)

1cycle (12,3%)

2cycles (32,7%)

3cycles (37,8%)

4cycles (363,81%)

2cycles (435,96%)

Allpatients (446)

Allpatients (451)

Patient choice

2 1

7 8

Died

Surgery (11,2%)

Surgery (400,89%)

Surgery (411,91%)

Surgery (8,2%)

Surgery (21,5%)

Surgery (27,6%)

Surgery (331,74%)

Surgery (387,87%)

Resection

Yes

387 94% 364 94% 1.000

No

24

23

6%

6%

Of the 798 who had surgery, 47 (24 CF, 23 ECX) had an open and close operation.

Alderson,Cunninghamet al ASCO 2015

Alderson,Cunninghamet al ASCO 2015

Post-op complications

TheRoyalMarsden

OE02 update Trial Design

Complication

CF (N=397)

ECX (N=376)

n

%

n

%

57%

62%

Any complication

225 107

234 126

27%

34%

Respiratory

Resectable carcinoma of the oesophagus

4%

5%

Thrombo-embolic

16 57 44 36 18 12

17 56 45 42 16 15

14%

15%

Infection

11%

12%

Cardiac

9%

11%

Surgery related

RANDOMISE

5%

4%

Haematological

3%

4%

Chylothorax

11%

10%

Anastomotic

44

38

CS Chemotherapy and then surgery

7%

7%

Other

28 34

28 30

S Surgery alone

9%

8%

Required revisional operation Died within 30 days Died within 90 days

2%

2%

8

10 20

4%

5%

17

Alderson,Cunninghamet al ASCO 2015

9